We are actively recruiting patients to a Phase 2 adult clinical trial, a Phase 1 adult clinical trial and a Phase 1/2 pediatric clinical trial for larotrectinib. We are also actively recruiting patients to a Phase 1 clinical trial for LOXO-292.
Larotrectinib, Loxo Oncology’s lead investigational therapy, is an oral, selective inhibitor of tropomyosin receptor kinase (TRK), a family of signaling proteins that play an important role in cellular communication and tumor growth. TRK genes, which encode for TRKs, can become abnormally fused to other genes, resulting in growth signals that can lead to cancer in many sites of the body.
Larotrectinib was purposely built to directly target TRK, and nothing else, turning off the signaling pathway that allows TRK fusion cancers to grow. Larotrectinib is the only selective TRK inhibitor in clinical development and is being studied in multiple clinical trials described below.
Patients with advanced cancer who seek out tumor profiling or comprehensive cancer genomic testing may discover that their tumor harbors a TRK fusion, as this genomic event has been described across many tumor types, including:
For more information about any of the larotrectinib clinical trials, please refer to www.clinicaltrials.gov or www.loxooncologytrials.com. Interested patients and physicians can contact the Loxo Oncology TRK Physician and Patient Clinical Trial Hotline at 1-855-NTRK-123 or email email@example.com.
LOXO-292 (RET inhibitor)
LOXO-292 is a potent, oral and selective investigational medicine in clinical development for the treatment of patients with cancers that harbor abnormalities in the rearranged during transfection (RET) kinase.
LOXO-292 was designed to inhibit both native RET signaling that drives tumor formation and progression and anticipated acquired resistance mechanisms that could limit the activity and effectiveness of this therapeutic approach, offering the potential for more effective and safe treatment of patients with RET-dependent cancers.
For more information about the LOXO-292 clinical trial, please refer to www.loxooncologytrials.com. Interested patients and physicians can contact the Loxo Oncology RET Physician and Patient Clinical Trial Hotline for more information about the LOXO-292 clinical trial at 1-855-RET-4-292 or email firstname.lastname@example.org.
LOXO-195 (TRK Inhibitor)
LOXO-195 is an investigational next-generation, selective TRK inhibitor capable of addressing and overcoming potential mechanisms of acquired resistance that may emerge in patients receiving larotrectinib or other multikinase inhibitors with anti-TRK activity.
Acquired resistance to targeted therapies has proven to be an important component of long-term cancer care and targeted therapy drug development. LOXO-195 was developed in anticipation of potential resistance to larotrectinib, and in light of recent published literature regarding emerging mechanisms of resistance to TRK inhibition. LOXO-195 is being developed as a sequential treatment, to follow larotrectinib or another TRK inhibitor, to extend the total time of benefit from TRK inhibition.
With the LOXO-195 program, Loxo Oncology has an opportunity to clinically extend the duration of disease control for patients with TRK-driven cancers.
For additional information about the LOXO-195 clinical trial, please refer to www.loxooncologytrials.com. Interested patients and physicians can contact the Loxo Oncology Physician and Patient Clinical Trial Hotline at 1-855-NTRK-123 or email email@example.com.
Larotrectinib (LOXO-101) is currently being evaluated in an ongoing multicenter, open-label, Phase 1 study in adult subjects with advanced solid tumors that have progressed or are non responsive to available therapies and for which no standard or available curative therapy exists.
In October 2015, we initiated a global, multi-center, single-arm, open-label Phase 2 basket trial in adult patients with solid tumors harboring TRK fusions. As a basket trial, the Phase 2 trial enrolls patients regardless of where their cancer arises in the human body, so long as the cancer harbors a TRK gene fusion.
In December 2015, we initiated a multicenter, open-label Phase 1 trial in pediatric patients with advanced solid or primary CNS tumors. The trial utilizes a liquid formulation of larotrectinib (LOXO-101) designed specifically for pediatric patients unable to swallow capsules.
LOXO-292, a potent, oral and selective investigational new drug in clinical development for the treatment of patients with cancers that harbor abnormalities in the rearranged during transfection (RET) kinase, is currently being evaluated in a global, multi-center Phase 1 trial in patients with advanced solid tumors.
LOXO-195 is currently being studied in a multi-center Phase 1/2 trial in patients with TRK fusion cancers who have progressed while receiving another TRK inhibitor or are intolerant to another TRK inhibitor.